Omega-3 fatty acids and cardiovascular disease

被引:5
作者
Jain, A. P. [1 ]
Aggarwal, K. K.
Zhang, P. -Y. [2 ]
机构
[1] MGIMS, Dept Med, Wardha, India
[2] Xuzhou Cent Hosp, Dept Cardiol, Xuzhou, Jiangsu, Peoples R China
关键词
Cardioceuticals; Omega-3 fatty acids; Cardioprotection; Eicosapentaenoic acid; Docosahexaenoic acid; N-3; FATTY-ACIDS; CORONARY-ARTERY-DISEASE; PRIMARY-PREVENTION; HYPERCHOLESTEROLEMIC PATIENTS; EICOSAPENTAENOIC ACID; SECONDARY-PREVENTION; DIABETES-MELLITUS; SERUM-LIPIDS; RISK-FACTORS; FISH-OIL;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cardioceuticals are nutritional supplements that contain all the essential nutrients including vitamins, minerals, omega-3-fatty acids and other antioxidants like a-lipoic acid and coenzyme Q10 in the right proportion that provide all round protection tothe heart by reducing the most common risks associated with the cardiovascular disease including high low-density lipoprotein cholesterol and triglyceride levels and factors that contribute to coagulation of blood. Omega-3 fatty acids have been shown to significantly reduce the risk for sudden death caused by cardiac arrhythmias and all-cause mortality in patients with known coronary heart disease. Omega-3 fatty acids are also used to treat hyperlipidemia and hypertension. There are no significant drug interactions with omega-3 fatty acids. The American Heart Association recommends consumption of two servings of fish per week for persons with no history of coronary heart disease and at least one serving of fish daily for those with known-coronary heart disease. Approximately 1 g/day of eicosapentaenoic acid plus docosahexaenoic acid is recommended for cardio protection. Higher dosages of omega-3 fatty acids are required to reduce elevated triglyceride levels (2-4 g/day). Modest decreases in blood pressure occur with significantly higher dosages of omega-3 fatty acids.
引用
收藏
页码:441 / 445
页数:5
相关论文
共 34 条
  • [1] Blood levels of long-chain n-3 fatty acids and the risk of sudden death.
    Albert, CM
    Campos, H
    Stampfer, MJ
    Ridker, PM
    Manson, JE
    Willett, WC
    Ma, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (15) : 1113 - 1118
  • [2] Atakisi O, 2013, EUR REV MED PHARMACO, V17, P467
  • [3] EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls
    Block, Robert C.
    Harris, William S.
    Reid, Kimberly J.
    Sands, Scott A.
    Spertus, John A.
    [J]. ATHEROSCLEROSIS, 2008, 197 (02) : 821 - 828
  • [4] Differentiating prescription omega-3-acid ethyl esters (P-OM3) from dietary-supplement omega-3 fatty acids
    Brunton, Stephen
    Collins, Nancy
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (05) : 1139 - 1145
  • [5] BURR ML, 1989, LANCET, V2, P757
  • [6] Primary prevention of cardiovascular diseases in people with diabetes mellitus - A scientific statement from the American Heart Association and the American Diabetes Association
    Buse, John B.
    Ginsberg, Henry N.
    Bakris, George L.
    Clark, Nathaniel G.
    Costa, Fernando
    Eckel, Robert
    Fonseca, Vivian
    Gerstein, Hertzel C.
    Grundy, Scott
    Nesto, Richard W.
    Pignone, Michael P.
    Plutzky, Jorge
    Porte, Daniel
    Redberg, Rita
    Stitzel, Kimberly F.
    Stone, Neil J.
    [J]. CIRCULATION, 2007, 115 (01) : 114 - 126
  • [7] Connor SL, 1997, AM J CLIN NUTR, V66, P1020
  • [8] Covington MB, 2004, AM FAM PHYSICIAN, V70, P133
  • [9] De Caterina R, 2000, AM J CLIN NUTR, V71, p213S, DOI 10.1093/ajcn/71.1.213S
  • [10] De Luis DA, 2009, EUR REV MED PHARMACO, V13, P51